Brooke Jennings, APRN
Nurse Practitioner · Zanesville, OHNPI 1184123473
Payments from drug & device makers
Across 105 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$101
- Boston Scientific$45
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$45
- GSK$45
- QOL Medical, LLC$44
- plus $388 from 18 others
What the payments were for
- Food & beverage$1,737100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,069 |
| AstraZeneca | 7 | $101 |
| Boston Scientific | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| GSK | 2 | $45 |
| QOL Medical, LLC | 2 | $44 |
| Lilly USA, LLC | 3 | $43 |
| Novo Nordisk | 3 | $42 |
| Exact Sciences | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Abiomed | 1 | $16 |
| Pfizer | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,737 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 24 | $28,012 |
| OzempicSemaglutide | 14 | $26,917 |
| JanuviaSitagliptin Phosphate | 22 | $20,168 |
| EliquisApixaban | 23 | $19,532 |
| MounjaroTirzepatide | 13 | $13,672 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,417 |
| SynthroidLevothyroxine Sodium | 31 | $1,498 |
| Duloxetine Hcl | 58 | $1,303 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,193 |
| Gabapentin | 106 | $1,113 |
| Losartan Potassium | 111 | $966 |
| Pantoprazole Sodium | 86 | $895 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 42 | $841 |
| Atorvastatin Calcium | 160 | $800 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $101 | $28,01224 claims |
| Novo NordiskOzempic | $42 | $26,91714 claims |
| PfizerEliquis | $15 | $19,53223 claims |
| Lilly USA, LLCMounjaro | $43 | $13,67213 claims |
| AbbVieSynthroid | $1,069 | $1,49831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Zanesville
- Kristen BurgessZanesville$10K
- Michelle DevollZanesville$10K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.